Can we predict responsiveness to hypomethylating agents in AML?

Stomper, Julia; Lübbert, Michael

Stomper, Julia; Lübbert, Michael.

Afiliação

Stomper J; Department of Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany.
Lübbert M; Department of Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany; German Cancer Research Consortium (DKTK), Freiburg, Germany. Electronic address: michael.luebbert@uniklinik-freiburg.de.

Semin Hematol ; 56(2): 118-124, 2019 04.

Article em En | MEDLINE | ID: mdl-30926087

Assuntos

Antineoplásicos/uso terapêutico; Metilação de DNA/genética; Leucemia Mieloide Aguda/tratamento farmacológico; Antineoplásicos/farmacologia; Humanos

Palavras-chave

DNA methylation; Epigenetics; Fetal hemoglobin; Monosomal karyotype; TP53

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Metilação de DNA / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google